key: cord-0833571-or94omzd authors: Valenti, Mario; Pavia, Giulia; Gargiulo, Luigi; Facheris, Paola; Nucca, Ombretta; Mancini, Luca; Sacrini, Francesco; Borroni, Riccardo G.; Narcisi, Alessandra; Costanzo, Antonio title: Impact of delay in follow‐up due to COVID‐19 pandemic on skin cancer progression: a real‐life experience from an Italian hub hospital date: 2021-03-04 journal: Int J Dermatol DOI: 10.1111/ijd.15501 sha: 2200986667261fe87510fe837f757f234082d698 doc_id: 833571 cord_uid: or94omzd BACKGROUND: The COVID‐19 pandemic required the setting of a national lockdown in Italy from March 9, 2020, until May 18, 2020; therefore, most of the non‐COVID‐19 activities were postponed. As a consequence, many follow‐up visits in patients with previously excised skin cancers were delayed. The aim of this retrospective real‐life case–control study is demonstrating that delay in follow‐up led to an increased incidence of advanced melanoma and keratinocyte cancers on the total of surgically excised skin cancers. METHODS: The incidence of excised advanced melanoma and keratinocyte cancers in our dermato‐surgery division in the period May 18 to November 18, 2020, was compared to the same time span of 2019. All data were collected from the electronic database of our department. Odds ratio with 95% confidence interval was used to assess the risk of excised advanced skin cancers in 2020 compared to 2019. RESULTS: From May to November 2019, we performed 265 surgical excisions, while during the pandemic in 2020, we completed 280 surgeries. The number of advanced skin cancers excised between May 18 and November 18, 2020, was significantly higher compared with the same period in 2019 (54 vs. 22, OR: 2.64; 95% CI: 1.56–4.47; P = 0.0003). Significant differences were also observed regarding the number of surgically removed advanced BCCs (OR 2.15; 95% CI 1.14–4.07; P = 0.0187) and advanced SCCs (OR 4.60; 95% CI 1.31–16.18; P = 0.0175). CONCLUSION: These results confirm that delay in follow‐up and, consequently, postponed surgical excisions are related to an increased incidence of advanced skin tumors, resulting in poorer prognosis lifelong. Follow‐up visits should be carried on even during COVID‐19 pandemic, avoiding significant delays as much as possible. Spreading of the COVID-19 pandemic required the setting of a national lockdown in Italy from March 9 until May 18, 2020; therefore, most of the non-COVID-19 activities were postponed. This new setting of a national health system has rapidly changed the approach to skin cancer screening and follow-up. In particular, many follow-up visits in patients with previously excised melanoma and keratinocyte cancers were delayed. Furthermore, the annual dermatologic checkup visits were frequently postponed. As a consequence, a substantial increase in the number of avoidable cancer deaths all over the world is expected as a result of diagnostic delays due to the COVID-19 pandemic. 1 During the pandemic, our Dermatology Department has continued to guarantee urgencies, clinical trials scheduled visits, follow-up of patients under treatment with biologics, and the most important dermato-oncology follow-up and urgent dermato-surgical procedures. 2, 3 However, many patients skipped their scheduled appointments due to logistic reasons or for fear of possible contagion. We hypothesized that the delay on diagnosis and follow-up has critically impacted tumor burden and progression of melanomas and keratinocyte cancers. To confirm this hypothesis, we have analyzed the database of our dermato-surgery division, assessing the incidence of advanced melanomas and advanced keratinocyte cancers during the period of May 18 to November 18, 2020, and compared these data with that of the same period of the previous year (May 18 to November 18, 2019). The definition of advanced tumors was determined on the basis of histological, surgical, and clinical criteria. This is a single-center retrospective real-life case-control study performed analyzing the electronic database of our dermatologic department. We considered a 6-month period, from May 18 to November 18, to compare the surgical activity of two consecutive years (2019 and 2020). We considered the 6-month period in 2020 (immediately after the first pandemic wave in Italy) as the case group and the same time span in 2019 as the control group. Of these patients, we analyzed demographics, tumor risk factors, and mean time occurring between the last two follow-up visits. All patients were followed up in our oncological dermatology clinic. All surgical excisions were performed by the same surgical team both in 2019 and in 2020. For this reason, operator-dependent factors were ruled out when analyzing data. We have chosen to define "advanced melanoma" (aM) as all melanomas with a pTNM staging of pT1b or more, based on the histological examination. We have considered as "advanced squamous cell carcinoma" (aSCC) the following categories: 1) G2/G3 squamous cell carcinomas 2) Squamous cell carcinomas whose excision required an advanced reconstructive surgery due to the tumor size or the location (e.g., grafts or flaps) 3) Squamous cell carcinomas that were not surgically removable but eligible for radiotherapy or immunotherapy or targeted therapy. Our definition of "advanced basal cell carcinoma" (aBCC) includes the following categories: 1) Basal cell carcinomas that were not totally excised due to their size or location 2) Basal cell carcinomas whose excision required an advanced reconstructive surgery due to the tumor size or the location (e.g., grafts or flaps) 3) Basal cell carcinomas that were not surgically removable but eligible for radiotherapy or chemotherapy or targeted therapy. The COVID-19 pandemic has deeply changed our routine clini- Our study has several limitations, the majority of them being that it is representative of only a single-center experience. Another limitation is due to our dermatologic activity being mainly targeted on high-risk patients sent from primary care services. Thus, many of the selected cases and controls were already at risk for developing advanced melanomas or keratinocyte cancers due to personal or familial dermatologic history, previous radiotherapy, previous or concomitant These results confirm the hypothesis that follow-up delay and, consequently, retarded surgical excision is related to an increased incidence of advanced skin tumors, resulting in poorer consequences for prognosis, aesthetic result, and therapeutic management. 9 Cancer patients' schedules should be carried on even during the COVID-19 pandemic, trying to minimize the delay between follow-up visits. We all need better models of cancer care and treatment during this pandemic in order to avoid both tumor burden and new contagions in the hospitals among our fragile patients. This report highlights the importance of maintaining a regular followup and avoiding, as much as possible, significant delays that could lead to skin tumor progression. As in the current environment, presenting for a clinical skin examination may be viewed as "not strictly necessary" and thus postponed; however, early detection of melanoma and keratinocyte cancers must be encouraged. Telehealth could be used for patients at highest risk of SARS-CoV-2 infection, including elderly patients with multiple risks factors for either skin cancers or respiratory infections, and others who are fearful of visiting doctors. Telemedicine also eliminates the risk of contagion for dermatologists and other healthcare workers. 10 In this context, technological diagnostic strategies such as telemedicine, that has already confirmed its value before and during this pandemic scenario, could represent a new possible support for dermato-oncologists. 11, 12 The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) Awareness and perceptions related to COVID-19 among cancer patients: a survey in oncology department Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective Gemelli Skin-Cancer Multidisciplianry Tumour Board (S-MDTB). Skin cancer triage and management during COVID-19 pandemic Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: a systematic review Skin cancer-the importance of prevention Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic Virtual melanoma checks during a pandemic Telediagnosis and face-to-face diagnosis reliability for melanocytic and nonmelanocytic 'pink' lesions Teledermatology in the era of COVID-19: experience of an academic department of dermatology